novo nordisk's semaglutide failed to slow alzheimer's disease progression reports 2 trial failures for GLP-1 in Novo Nordisk Stock Slumps After

Mann JFE, Rossing P, Bakris G et al (2024) Effects of semaglutide with and without concomitant SGLT2 inhibitor use in participants with type 2 diabetes and chronic kidney disease in the FLOW trial

#NovoNordisk #EliLilly #Semaglutide #GLP1 #ObesityTreatment #DiabetesCare #PharmaIndustry #PharmaNews #HealthcareInnovation #Biopharma #ETPharma #DrugMarket Interesting to note that ET's team does not realize the "obesity market" In India is currently "off-label" and, therefore, "OFF-LIMITS"

Delivered via subcutaneous injection, Nova B12 provides steady release and superior absorption compared to oral forms, ensuring consistent elevation of B12 levels

I wanna move well as I age

Potential Impact of Oxidation Oxidative modifications may alter: Biological activity Peptide stability Receptor binding affinity Overall therapeutic performance Analytical Challenges Sensitive LC-HRMS workflows are commonly used to accurately identify and quantify oxidative degradation products